MedTrace Logo

Empagliflozin for the Treatment of Postprandial Hypoglycemia

NCT05036317 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-08-16

No results posted yet for this study

Summary

This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

Conditions

  • Postprandial Hypoglycemia

Interventions

DRUG

Empagliflozin (Jardiance®;

Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.

OTHER

Placebo Control Intervention

Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.

Sponsors & Collaborators

Principal Investigators

  • Marc Y Donath, Prof. Dr. med. · University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2024-08-05
Completion
2024-08-05

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036317 on ClinicalTrials.gov